Intramuscular self-amplifying RNA and adenoviral RSV vaccines program distinct systemic and respiratory mucosal immune architectures.
Respiratory syncytial virus (RSV) remains a major cause of severe lower respiratory tract disease in infants, older adults, and immunocompromised individuals, underscoring the need for vaccine strategies that balance systemic protection with frontline respiratory immunity. Although adenoviral and RNA-based RSV are both...